Navigation Links
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Date:2/24/2011

WAYNE, N.J. and EMERYVILLE, Calif., Feb. 24, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer. This Phase 3 trial was initiated based on the results from a cooperative group-sponsored Phase 2 clinical trial evaluating Nexavar in combination with capecitabine in patients with advanced breast cancer.

"This Phase 3 trial is an important milestone in our development of Nexavar as it provides an opportunity to evaluate Nexavar in this patient population," said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. "We look forward to continuing our breast cancer clinical trial program, which includes two ongoing cooperative group-sponsored Phase 2 trials."

Phase 3 Trial Design

The RESILIENCE (Phase 3 TRial Comparing CapecitabinE in Combination with SorafenIb or PLacebo for Treatment of Locally Advanced or MetastatIc HER2–Negative Breast CancEr) trial is a randomized, double-blind, placebo-controlled Phase 3 study planned to enroll 519 patients in more than 20 countries including the United States, Brazil, Japan and Australia. The study will evaluate Nexavar in combination with capecitabine in patients with locally advanced or metastatic HER-2 negative breast cancer who are resistant to or have failed prior taxane and an anthracycline or for whom further anthracycline is not indicated. The primary endpoint of the study is progression-free survival. Secondary endpoints include
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... 2014 Animal Emergency Critical Care, a LifeCentre partner practice, located ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a well-seasoned ... Cole Taylor , are avid scuba divers. "As altitude skiers ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... OncoSec Medical Incorporated (OTCBB: ONCS), which is ... solid tumor cancers, announced today clinical study results ... Future of Ablation Therapies conference in Las Vegas, ... titled, "OMS ElectroChemotherapy: Targeted Ablation of Solid Tumors ...
... Nonin Medical, Inc., the inventor of finger pulse ... announced the launch of the Onyx® Vantage 9590 professional ... 2011 Annual Congress in The Netherlands. The Onyx® Vantage ... the presence of low perfusion. The new device features ...
Cached Medicine Technology:Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials 2Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials 3Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials 4Nonin Medical Launches Onyx® Vantage 9590 Professional Finger Pulse Oximeter at ERS Annual Congress 2
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... in PLOS Pathogens , children who live in ... mount an immune response to infection with malaria parasites ... high fever and illness and partially control the growth ... help researchers develop future interventions that prevent or mitigate ... year, approximately 200 million cases of malaria occur worldwide, ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... ... Awards Ceremony Reminded Everyone of the Importance of One Simple Thing: Good Posture. ... (PRWEB) March 11, ... poor posture of some presenters than on the Vera Wang dresses or breakout performances ...
... ... of $25 or more for all hand and body lotions as well as facial serums. ... Southfield, Mich. (PRWEB) March ... lotions with an emphasis on the key ingredient African Shea butter. The products are highly ...
... ... few weeks, thousands of college students across the U.S. will travel abroad ... abusive drinking. Kathleen Quartaro, a Choose Responsibility volunteer and mother of a ... drinking during her freshman year, urges parents and students to discuss the ...
... ... put an end to decades of unethical and disinterested leadership in Northern Manhattan by supporting ... ... 2010 -- After decades of serving the men and women of New York City through ...
... ... Houston and will soon be expanding nationwide. Local IT Companies connects businesses with up to ... , ... It seems most business owners are entrenched in their own day to day business building ...
... ... company that takes pride in providing accurate information on sexuality and toys for grown-ups, ... , ... March 11, 2010 -- Good Vibrations , the legendary San Francisco-based company that takes ...
Cached Medicine News:Health News:Slouching Stars at the Oscars: Could the PostureNOW Posture Brace Have Helped Miley? 2Health News:Free Shipping On Hand and Body Lotions Made with African Shea Butter 2Health News:Mother of Binge Drinking Victim Urges Students and Parents to Discuss Signs of Alcohol Poisoning, Emphasize Peer Responsibility Prior to Spring Break 2Health News:Rev. Michel Faulkner Seeks to Retire Charlie Rangel from New York's 15th Congressional Seat 2Health News:Rev. Michel Faulkner Seeks to Retire Charlie Rangel from New York's 15th Congressional Seat 3Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 3Health News:Good Vibrations' Pleasure-Ed Series Brings High Quality Erotic Education to the Classroom and the Bedroom 2
... Healthcare is known as ... analysis programs for every ... device. With advanced programs ... and ACI-TIPI, GE can ...
For use in vitreo-retinal procedures with a non contact system, and compatible with the Oculus BIOM system, this lens delivers the highest image clarity available in a non contact surgical lens....
... Affinity pacemaker family offers ... truly automatic devices. Featuring ... of advanced technologies ever ... pacemaker incorporates the exclusive ...
... family features St. Jude Medical's ... lead is available in both ... silicone (IsoFlex S lead) models, ... and multiple lead lengths, providing ...
Medicine Products: